KR20180066264A - 세펨 화합물, 그의 제조 및 용도 - Google Patents

세펨 화합물, 그의 제조 및 용도 Download PDF

Info

Publication number
KR20180066264A
KR20180066264A KR1020187015784A KR20187015784A KR20180066264A KR 20180066264 A KR20180066264 A KR 20180066264A KR 1020187015784 A KR1020187015784 A KR 1020187015784A KR 20187015784 A KR20187015784 A KR 20187015784A KR 20180066264 A KR20180066264 A KR 20180066264A
Authority
KR
South Korea
Prior art keywords
amino
methyl
azabicyclo
oct
thia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187015784A
Other languages
English (en)
Korean (ko)
Inventor
사마렌드라 네이스 마이티
다이 꾸옥 응위엔
안드에 브이.엔. 레디
주디 입
찬 민 하
롱 링
루동 산
마드하바 레디 마달라
Original Assignee
나에자-알지엠 파마슈티칼스 유엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 나에자-알지엠 파마슈티칼스 유엘씨 filed Critical 나에자-알지엠 파마슈티칼스 유엘씨
Publication of KR20180066264A publication Critical patent/KR20180066264A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/48—Methylene radicals, substituted by hetero rings
    • C07D501/56—Methylene radicals, substituted by hetero rings with the 7-amino radical acylated by carboxylic acids containing hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/02—Preparation
    • C07D501/04—Preparation from compounds already containing the ring or condensed ring systems, e.g. by dehydrogenation of the ring, by introduction, elimination or modification of substituents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cephalosporin Compounds (AREA)
KR1020187015784A 2015-12-10 2016-12-05 세펨 화합물, 그의 제조 및 용도 Ceased KR20180066264A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562265625P 2015-12-10 2015-12-10
US62/265,625 2015-12-10
PCT/CA2016/051428 WO2017096472A1 (en) 2015-12-10 2016-12-05 Cephem compounds, their production and use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197010752A Division KR102135230B1 (ko) 2015-12-10 2016-12-05 세펨 화합물, 그의 제조 및 용도

Publications (1)

Publication Number Publication Date
KR20180066264A true KR20180066264A (ko) 2018-06-18

Family

ID=59012429

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197010752A Expired - Fee Related KR102135230B1 (ko) 2015-12-10 2016-12-05 세펨 화합물, 그의 제조 및 용도
KR1020187015784A Ceased KR20180066264A (ko) 2015-12-10 2016-12-05 세펨 화합물, 그의 제조 및 용도

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020197010752A Expired - Fee Related KR102135230B1 (ko) 2015-12-10 2016-12-05 세펨 화합물, 그의 제조 및 용도

Country Status (13)

Country Link
US (2) US9751894B2 (enExample)
EP (1) EP3386977A4 (enExample)
JP (1) JP6967000B2 (enExample)
KR (2) KR102135230B1 (enExample)
CN (1) CN108463461B (enExample)
AU (1) AU2016367284C1 (enExample)
BR (1) BR112018009725A8 (enExample)
CA (1) CA3005779C (enExample)
EA (1) EA039648B1 (enExample)
HK (1) HK1254209A1 (enExample)
IL (1) IL259234B (enExample)
WO (1) WO2017096472A1 (enExample)
ZA (1) ZA201802654B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102019115536A1 (de) 2018-06-08 2019-12-12 Lg Display Co., Ltd. Dehnbare anzeigevorrichtung, panelansteuerungsschaltkreis und ansteuerungsverfahren davon

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017096472A1 (en) 2015-12-10 2017-06-15 Naeja-Rgm Pharmaceuticals Inc. Cephem compounds, their production and use
EP3687992A1 (en) * 2017-09-27 2020-08-05 Meiji Seika Pharma Co., Ltd. Crystalline forms of diazabicyclooctane derivatives and production process thereof
TWI795549B (zh) * 2018-04-06 2023-03-11 日商富士軟片股份有限公司 新穎青黴烷衍生物或其鹽、醫藥組成物及其應用
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
ES2960952T3 (es) 2018-08-09 2024-03-07 Antabio Sas Diazabiciclooctanonas como inhibidores de serina beta-lactamasas
US12257307B2 (en) 2019-06-24 2025-03-25 Diverse Biotech, Inc. β-lactam-cannabinoid conjugate molecules

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3118732A1 (de) * 1981-05-12 1982-12-02 Hoechst Ag, 6000 Frankfurt Cephalosporinderivate und verfahren zu ihrer herstellung
US4406899A (en) 1982-03-04 1983-09-27 Bristol-Myers Company Cephalosporins
IL77458A (en) * 1985-01-14 1990-07-26 Eisai Co Ltd Cephem derivatives,their production and antibacterial compositions containing them and certain novel intermediates therefor
ATE89826T1 (de) * 1985-03-01 1993-06-15 Takeda Chemical Industries Ltd Antibakterielle verbindungen, ihre herstellung und verwendung.
US4910301A (en) 1985-08-05 1990-03-20 Bristol-Myers Company Cefepime cephalosporin salts
US4777128A (en) 1986-05-27 1988-10-11 Ethigen Corporation Fluorescence immunoassay involving energy transfer between two fluorophores
GB8805642D0 (en) 1988-03-09 1988-04-07 Fujisawa Pharmaceutical Co New cephem compounds & processes for preparation thereof
US5173485A (en) 1988-03-09 1992-12-22 Fujisawa Pharmaceutical Company, Ltd. Cephem compounds
US5215982A (en) * 1989-11-10 1993-06-01 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
CA2216259A1 (en) 1996-09-25 1998-03-25 Eisai Chemical Co., Ltd. Production process of cephem compound
TW526202B (en) * 1998-11-27 2003-04-01 Shionogi & Amp Co Broad spectrum cephem having benzo[4,5-b]pyridium methyl group of antibiotic activity
JP2003026679A (ja) * 2001-07-10 2003-01-29 Banyu Pharmaceut Co Ltd 新規カルバペネム誘導体
TW200305422A (en) * 2002-03-18 2003-11-01 Shionogi & Co Broad spectrum cefem compounds
WO2004039814A1 (en) 2002-10-30 2004-05-13 Astellas Pharma Inc. Cephem compounds
US20090012054A1 (en) 2006-03-16 2009-01-08 Astellas Pharma Inc. Cephem Compounds and Use as Antimicrobial Agents
CN101343281A (zh) * 2007-04-20 2009-01-14 山东轩竹医药科技有限公司 新型脒基吡啶基头孢菌素类化合物
EA019520B1 (ru) * 2008-10-31 2014-04-30 Сионоги Энд Ко., Лтд. Цефалоспорины, содержащие катехольную группу
RU2012146986A (ru) 2010-04-05 2014-05-20 Сионоги Энд Ко., Лтд. Цефемовые соединения, содержащие катехольную группу
JP5852559B2 (ja) 2010-04-05 2016-02-03 塩野義製薬株式会社 擬似カテコール基を有するセフェム化合物
WO2011136268A1 (ja) 2010-04-28 2011-11-03 塩野義製薬株式会社 新規なセフェム誘導体
DK2590978T3 (en) * 2010-06-18 2018-01-02 Fob Synthesis Inc CARBAPENEM ANTIBACTERIAL AGENTS WITH GRAM-NEGATIVE ACTIVITY
KR101719556B1 (ko) 2011-03-30 2017-03-24 주식회사 레고켐 바이오사이언스 신규한 세파로스포린 유도체 및 이를 함유하는 의약 조성물
WO2012147773A1 (ja) * 2011-04-28 2012-11-01 塩野義製薬株式会社 カテコールまたは擬似カテコール構造を有する新規セフェム化合物
JP2013012630A (ja) 2011-06-30 2013-01-17 Toyota Industries Corp 熱電変換モジュール
TWI547496B (zh) 2011-10-04 2016-09-01 葛蘭素集團公司 抗菌化合物
JPWO2013051597A1 (ja) 2011-10-04 2015-03-30 塩野義製薬株式会社 カテコール基を有するセフェム誘導体
US8809314B1 (en) * 2012-09-07 2014-08-19 Cubist Pharmacueticals, Inc. Cephalosporin compound
UY35103A (es) * 2012-10-29 2014-05-30 Glaxo Group Ltd Compuestos de cefem 2-sustituidos
WO2014087165A1 (en) 2012-12-06 2014-06-12 University Of Bath Tankyrase inhibitors
JPWO2014104148A1 (ja) * 2012-12-26 2017-01-12 塩野義製薬株式会社 セフェム化合物
WO2017096472A1 (en) 2015-12-10 2017-06-15 Naeja-Rgm Pharmaceuticals Inc. Cephem compounds, their production and use

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102019115536A1 (de) 2018-06-08 2019-12-12 Lg Display Co., Ltd. Dehnbare anzeigevorrichtung, panelansteuerungsschaltkreis und ansteuerungsverfahren davon

Also Published As

Publication number Publication date
KR20190042752A (ko) 2019-04-24
HK1254209A1 (zh) 2019-07-12
AU2016367284A1 (en) 2018-05-10
USRE48097E1 (en) 2020-07-14
CN108463461B (zh) 2021-11-19
WO2017096472A1 (en) 2017-06-15
ZA201802654B (en) 2019-07-31
CA3005779C (en) 2020-04-07
EA201891381A1 (ru) 2019-01-31
EA039648B1 (ru) 2022-02-21
CN108463461A (zh) 2018-08-28
KR102135230B1 (ko) 2020-07-17
BR112018009725A2 (pt) 2018-11-06
US9751894B2 (en) 2017-09-05
US20170166587A1 (en) 2017-06-15
EP3386977A4 (en) 2019-05-22
JP6967000B2 (ja) 2021-11-17
BR112018009725A8 (pt) 2019-02-26
JP2018536678A (ja) 2018-12-13
IL259234B (en) 2018-12-31
AU2016367284B2 (en) 2018-05-17
CA3005779A1 (en) 2017-06-15
AU2016367284C1 (en) 2018-09-20
EP3386977A1 (en) 2018-10-17

Similar Documents

Publication Publication Date Title
KR20180066264A (ko) 세펨 화합물, 그의 제조 및 용도
US10227331B2 (en) Metallo-β-lactamase inhibitors
US11142526B2 (en) Spirocycle compounds and methods of making and using same
CA2952692A1 (en) Substituted imidazo[1,2b]pyridazine compounds
KR20140140625A (ko) 베타-락타마제 억제제로서의 헤테로비시클릭 화합물
JP2010215652A (ja) β−ラクタマーゼ阻害剤としての二環式６−アルキリデン−ペネム
US9839642B2 (en) Beta-tetrazolyl-propionic acids as metallo-beta-lactamase inhibitors
AU2002211827B2 (en) Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same
EP3630111B1 (en) Compounds and methods for treating bacterial infections
US7056917B2 (en) Drug efflux pump inhibitor
JP4472515B2 (ja) ベータ−ラクタマーゼ阻害剤としてのヘテロトリサイクリル−６−アルキリデン−ペネム
JP4233610B2 (ja) 新規カルバペネム誘導体
JP2008542376A (ja) クラスＤのβラクタマーゼ阻害剤としての三環系６−アルキリデンペネム類
KR970005844B1 (ko) 새로운 세파로스포린 화합물 및 항균제
JPS59231091A (ja) ７−オキソ−４−チア−１−アザビシクロ〔３．２．０〕ヘプタ−２−エン誘導体
CA3059773C (en) Compounds and methods for treating bacterial infections
CA3246901A1 (en) C-MYC MESSENGER RIBONUCLE ACID (MRNA) TRANSLATION MODULATORS AND THEIR USES IN CANCER TREATMENT
HK40026676B (en) Compounds and methods for treating bacterial infections

Legal Events

Date Code Title Description
A201 Request for examination
A302 Request for accelerated examination
AMND Amendment
PA0105 International application

Patent event date: 20180604

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180604

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20180604

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

AMND Amendment
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20181025

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190131

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20181025

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20190131

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20181224

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20180618

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20180604

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20190315

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20190228

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20190131

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20181224

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20181025

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20180618

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20180604

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190415